26 Cases of Intractable Membranous Nephropathy Glucocorticoid Combined Gilad Amine Clinical Curative Effect Observation

Abstract

To study the clinical effect of glucocorticoid combined with thalidomide in the treatment of refractory nephrotic syndrome with membranous nephropathy. Methods: the pathological for membranous nephropathy of 26 patients with refractory nephrotic syndrome, glucocorticoid + gilad amine 50 mg 2 times/d, to turn the urine protein application again after 12 weeks after the reduction of 50 mg, l/d, maintain half year outage. The invalid was given a maximum of 24 weeks to stop the drug. The observation time was 24 weeks. Results: 24h urine protein decreased from 9.15 ±3.23 to 1.43±1.91 (P<0.01).Plasma albumin rose from 26.02 ± 6.75 to 35.57 ±4.02 (P<0.01). In most cases, the onset time was between 8 and 16 weeks, with a total relief of 30.77% in 24 weeks and 50.00% in partial relief, with a total effective rate of 80.77%.The main side effects are: rash, lethargy, fatigue, dizziness. No liver and kidney damage, bone marrow suppression. Conclusion: thalidomide combined with glucocorticoid is effective in the treatment of membranous nephropathy, with mild side effects, which provides a new way for the treatment of refractory membranous nephropathy.